I et flerdosisforsøg med PREZISTA, co- administreret med ritonavir, 600/ 100 mg to gange dagligt, blev det vist, at de totale plasmakoncentrationer af darunavir hos forsøgspersoner med mild (Child- Pugh klasse A, n=8) og moderat (Child- Pugh klasse B, n=8) nedsat leverfunktion var sammenlignelige med dem, der sås hos raske forsøgspersoner.
In a multiple dose study with PREZISTA co-administered with ritonavir (600/100 mg) twice daily, it was demonstrated that the total plasma concentrations of darunavir in subjects with mild (Child-Pugh Class A, n=8) and moderate (Child-Pugh Class B, n=8) hepatic impairment were comparable with those in healthy subjects.